Abstract
Breast cancer is the most diagnosed form of malignant tumour in Iraqi women. Tamoxifen and trastuzumab are highly effective adjuvant therapy for breast cancer.
 This study's objectives were to define the patient's belief in tamoxifen or trastuzumab when used as adjuvant therapy and to determine the variation in belief between the two medications in a sample of Iraqi breast cancer patients.
 The cross-section survey was conducted using the BMQ-Specific questionnaire. Ninety-seven participants (sixty-seven tamoxifen, thirty trastuzumab) participated in this study.
 The mean of specific-necessity scale for tamoxifen was (3.7) and for trastuzumab (4). The findings showed a high necessity for both medicines, and there were no significant differences in the scale of necessity between the two treatments. Regarding the scale of concern, the trastuzumab group's values are higher (3.35) than tamoxifen (3). Most participants who use tamoxifen or trastuzumab strongly agree with or agree with all the questions on the necessity scale with higher percentages for trastuzumab. Besides, the concern scale results showed the percentage of patients who agree / strongly agree is higher in the trastuzumab group. For the correlation between the need or concern score, the result showed only one significant negative correlation (R=-0.366, P-value=0.011) between the necessity score and the age of the participants for tamoxifen users. In Conclusion, this survey clearly showed a high level of necessity and a high level of concern regarding the use of two effective adjuvant therapy for women with breast cancer, tamoxifen and trastuzumab. Furthermore, this study shows that while the level of need for tamoxifen is higher than for trastuzumab, there were no significant variations between them.
Highlights
Metastasized breast cancer, Breast cancer is one of the most prevalent cancers among women[1]
This study investigates the beliefs concerning Tamoxifen and Trastuzumab, which are two effective and widely used adjuvant therapies prescribed for breast cancer patients
The authors did not discuss the quality of contact between the clinician and the patient, which could affect women's awareness, comprehension and beliefs about the two medications. This survey clearly showed a high level of necessity and concern regarding the use of two effective adjuvant therapies for women with breast cancer, Tamoxifen and Trastuzumab
Summary
Metastasized breast cancer, Breast cancer is one of the most prevalent cancers among women[1]. A selective estrogen receptor modulator (SERM), was the standard adjuvant endocrine therapy that can be used for five years, according to the American Society of Clinical Oncology Clinical Practice[8]. Tamoxifen is used to treat both early and advanced estrogen receptor-positive (ERpositive or ER+) breast cancer in pre-and postmenopausal women[9]. Adjuvant endocrine therapies are noted to have a substantial side effect profile that may negatively impact the quality of life and have been cited as obstacles to enduring care[14]. The clinical challenge of adjuvant drug therapy for metastasized breast cancer primarily pursues two goals: first, achieving high effectiveness in progression-free survival and avoiding therapyinduced and disease-related side effects at the same time is essential; second, preserving the best possible quality of life of the patient[15]. Since Tamoxifen or Trastuzumab can only achieve therapeutic benefits when taken as prescribed, it is necessary to examine patient noncompliance with treatments[16]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call